On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a two-day virtual meeting, Advancing Psychedelic Clinical Study Design.
The below commentary, written by Psychedelic Alpha’s Josh Hardman, is certainly not exhaustive, but rather aims to share a selection of observations from the event. It’s ordered broadly chronologically.
This second issue covers Day 2 of the meeting. If you haven’t already, you can read Day 1 coverage here.
In this article:
- Set and Setting
- Avoiding Pharmacological Essentialism: Ido Hartogsohn
- The Kitchen Table Debate: David Yaden
- Discussion
- Tiffany Farchione Provides an Overview of FDA Regulatory Authority
- Considerations for Potential Psychedelic Use in the Real World (Discussion)
This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
